You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

30 Results
Drug
Other Name(s): Hydrea®
Mar 2023
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Sep 2019
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
ODB - General Benefit
    hydroxyurea
Mar 2023
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB Limited Use
    lenalidomide - For the treatment of patients with multiple myeloma, who are deemed to be lenalidomide sensitive, and/or has not experienced progression while on a lenalidomide-based regimen in a treatment or maintenance setting, according to clinical criteria
ODB - General Benefit
    dexamethasone
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
Exceptional Access Program
    pomalidomide - For patients with relapsed and/or refractory multiple myeloma, according to specific criteria.
ODB - General Benefit
    dexamethasone
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab - In Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma
New Drug Funding Program
    Daratumumab in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Transplant Ineligible Multiple Myeloma
ODB - General Benefit
    dexamethasone
ODB Limited Use
    lenalidomide - For the treatment of patients with multiple myeloma, who are deemed to be lenalidomide sensitive, and/or have not experienced progression while on a lenalidomide-based regimen in the treatment or maintenance setting, according to clinical criteria
Sep 2022
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Intent: Palliative
Funding:
ODB - General Benefit
    hydroxyurea
Mar 2023

Pages